Post-translational modifications of immune checkpoints: unlocking new potentials in cancer immunotherapy [0.03%]
免疫检查点的翻译后修饰：解锁癌症免疫治疗的新潜力
Qiongjie Hu,Yueli Shi,Huang Wang et al.
Qiongjie Hu et al.
Immunotherapy targeting immune checkpoints has gained traction across various cancer types in clinical settings due to its notable advantages. Despite this, the overall response rates among patients remain modest, alongside issues of drug r...
Engineered circular RNA-based DLL3-targeted CAR-T therapy for small cell lung cancer [0.03%]
基于工程化环状RNA的DLL3靶向CAR-T治疗小细胞肺癌
Jingsheng Cai,Zheng Liu,Shaoyi Chen et al.
Jingsheng Cai et al.
Purpose: Circular RNA (circRNA) has emerged as a promising RNA therapeutic molecule due to its enhanced stability and prolonged protein expression compared to messenger RNA (mRNA). Using circRNA to construct transient Chi...
Efficacy and safety of immune checkpoint inhibitors in metastatic penile squamous cell carcinoma: a retrospective multicenter analysis [0.03%]
免疫检查点抑制剂在转移性阴茎鳞状细胞癌中的有效性和安全性：一项回顾性多中心分析
Timothy Schieber,Kelly Brunk,Anna Clennon et al.
Timothy Schieber et al.
Penile squamous cell carcinoma (PSCC) is a rare malignancy, and first-line therapy typically involves cisplatin-based chemotherapy. However, these regimens are often unsuitable for patients with poor performance status or advanced age due t...
Exosomal PD-L1 and lactate versus tissue PD-L1 as biomarkers for clinical outcomes of PD-1 Blockade plus chemotherapy in metastatic esophagogastric signet ring cell carcinoma [0.03%]
exoPD-L1和乳酸对比组织PD-L1作为预测PD-1抑制剂联合化疗治疗转移性食管胃印戒细胞癌的疗效biomarker研究
Yuanyuan Tian,Wei Shi,Jing Wang et al.
Yuanyuan Tian et al.
In this investigator-initiated, prospective, exploratory study, biomarkers predictive of clinical outcomes of first-line immune checkpoint inhibitor (ICI, nivolumab or pembrolizumab) plus XELOX(oxaliplatin and capecitabine) were identified ...
Lactylation modification in cancer: mechanisms, functions, and therapeutic strategies [0.03%]
癌症中的乳酰化修饰：机制、功能及治疗策略
Mengqi Lv,Yefei Huang,Yansu Chen et al.
Mengqi Lv et al.
Cancer remains the leading cause of mortality worldwide, and the emergence of drug resistance has made the identification of new therapeutic targets imperative. Lactate, traditionally viewed as a byproduct of glycolysis with limited ATP-pro...
Development of a bispecific antibody-drug conjugate targeting EpCAM and CLDN3 for the treatment of multiple solid tumors [0.03%]
针对多种实体瘤的EpCAM和CLDN3双特异性抗体药物的研发
Meiying Luo,Xiaohuan Wang,Guoji Yu et al.
Meiying Luo et al.
Epithelial cell adhesion molecule (EpCAM), a tumor antigen for antibody-drug conjugates (ADCs), is highly expressed in many epithelial cancers. However, the clinical progress of EpCAM ADCs has been challenging, primarily due to their toxici...
Bone marrow sympathetic neuropathy is a hallmark of hematopoietic malignancies and it involves severe ultrastructural damage [0.03%]
骨髓交感神经病变是造血恶性肿瘤的标志，伴有严重的超微结构损伤
Aurora Bernal,Vincent Cuminetti,Marc Serulla et al.
Aurora Bernal et al.
The hematopoietic stem cell (HSC) niche in the bone marrow (BM) supports HSC function, fate and numbers [1]. Sympathetic fibres innervate the BM and are components of the hematopoietic stem and progenitor cell (HSPC) niche [2]. Neuropathy o...
Matching-adjusted indirect comparison of efficacy and safety of lisocabtagene maraleucel and mosunetuzumab for the treatment of third-line or later relapsed or refractory follicular lymphoma [0.03%]
lisocabtagene maraleucel与mosunetuzumab治疗三线或以上复发/难治性滤泡性淋巴瘤的疗效和安全性匹配调整间接对比分析
Loretta J Nastoupil,Ashley Bonner,Pearl Wang et al.
Loretta J Nastoupil et al.
Background: The treatment landscape for relapsed or refractory (R/R) follicular lymphoma (FL) has changed with the introduction of anti-CD19 chimeric antigen receptor T-cell therapies, including lisocabtagene maraleucel (...
Ibrutinib and acalabrutinib use and risk of incident atrial fibrillation: a propensity-matched analysis [0.03%]
伊布替尼及阿卡拉布鲁定的使用与房颤发生风险：倾向性评分配对分析
Joachim Alexandre,Jonaz Font,Thibault Lenormand et al.
Joachim Alexandre et al.
Ibrutinib and acalabrutinib are both associated with an increased risk of atrial fibrillation (AF); however, the comparative risk of AF between these 2 BTK inhibitors remains largely unknown. Our primary aim was to evaluate the risk of inci...
Mesothelin-targeted CAR-T cells secreting NKG2D-BiTEs exhibit potent efficacy against triple-negative breast cancer [0.03%]
靶向间皮素的CAR-T细胞分泌NKG2D-BiTEs对三阴性乳腺癌有显著疗效
Muhammad Auwal Saliu,Qi Wang,Mansur Dabai Salisu et al.
Muhammad Auwal Saliu et al.
Triple-negative breast cancer (TNBC) is an aggressive subtype with poor prognosis and limited treatment options. Chimeric antigen receptor (CAR)-T cell therapy holds promise, but its efficacy is hindered by tumor antigen escape and heteroge...